Logo

NeuClone Reports Positive Results of NeuLara (biosimilar- ustekinumab) in P-l Study for Autoimmune Diseases

Share this

NeuClone Reports Positive Results of NeuLara (biosimilar- ustekinumab) in P-l Study for Autoimmune Diseases

Shots:

  • The P-I clinical trial involves assessing of a single dose of either NeuLara- US- or EU-sourced Stelara in ~200 healthy volunteers. NeuLara is NeuClone’s second biosimilar to have met all 1EPs & 2EPs in a three-arm P-I study
  • Result: the study met all co-primary PK endpoints for Cmax and AUC. For all PK 1EPs- CI (90%) of the GMR within the pre-specified (80%-125%) acceptance limits for all 3 pairwise comparisons. Additionally- the safety- immunogenicity and tolerability profiles were similar in all three treatment arms
  • NeuLara is a biosimilar referencing Stelara- being developed to treat patients with PsO- PsA- CD and UC. The biosimilar is being co-developed by NeuClone and its strategic manufacturing partner- Serum Institute of India

 ­ Ref: Neuclone | Image: Business Wire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions